Randomized controlled trial meets primary endpoint and finds statistically significant durable patient benefit 3.4 years post-treatmentHOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGener...